UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $63.13 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• UBS Asset Management reduced its Medpace stake by 15.3% in the second quarter, selling 21,601 shares and retaining 119,206 shares worth approximately $63.13 million. Institutional investors and hedge funds collectively own 77.98% of the company.
• Analyst targets range from $515 to $692, but the consensus rating remains “Hold” with an average price target of $595.20. Jefferies downgraded the stock to Hold, while RBC upgraded its target and maintained an Outperform rating.
• Medpace exceeded quarterly expectations, reporting $4.25 in EPS versus the $3.98 consensus and $707.33 million in revenue, up 17.2% year over year. Meanwhile, insiders sold 134,471 shares worth $82.15 million over the past 90 days.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,206 shares of the company's stock after selling 21,601 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.43% of Medpace worth $63,130,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. NewEdge Advisors LLC boosted its holdings in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock worth $319,000 after acquiring an additional 190 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Medpace during the second quarter valued at approximately $296,000. M&T Bank Corp raised its position in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company's stock worth $295,000 after purchasing an additional 31 shares during the period. Finally, First Trust Advisors LP raised its position in shares of Medpace by 105.2% during the second quarter. First Trust Advisors LP now owns 42,219 shares of the company's stock worth $13,251,000 after purchasing an additional 21,641 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent research reports. Leerink Partners set a $620.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and boosted their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Royal Bank Of Canada upped their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Finally, BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $595.20.

Insider Activity

In other Medpace news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the sale, the director owned 27,825 shares in the company, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This represents a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 134,471 shares of company stock valued at $82,151,311 over the last ninety days. Company insiders own 20.50% of the company's stock.

Medpace Trading Up 1.7%

Shares of Medpace stock opened at $593.02 on Thursday. The stock has a fifty day simple moving average of $571.91 and a 200 day simple moving average of $497.71. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The company has a market capitalization of $16.55 billion, a P/E ratio of 34.76, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business's revenue was up 17.2% on a year-over-year basis. During the same period last year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source